Aisling Capital related stories
All articles and analysis
Ambit Biosciences Closes $25M of Planned $50M RoundAmbit Biosciences Inc. has closed a $25 million of a new $50 million financing, the company announced. Existing investor OrbiMed Advisors led the financing with participation from other existing investors including Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. Ambit is a biopharmaceutical company developing “small molecule kinase inhibitors” for the treatment of cancer, inflammatory disease and other conditions.
- Phizer Buys VC-Backed NextWave Pharmaceuticals
Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round /92772/nextwave-pharmaceuticals-secures-45-million-in-financing/ last January.
- Aragon Pharmaceuticals Nabs $50M
Aragon Pharmaceuticals has closed a $50 million Series D round, the company announced Thursday. Aragon is developing therapeutics for hormone-driven cancers. venBio led the financing with participation from existing investors Topspin Fund, Aisling Capital, OrbiMed Advisors and The Column Group.
- Promising Venture Portfolios Lift Outlook At Indiana Pension Fund: Slideshow
The Indiana Public Retirement System began building a venture portfolio in earnest in 2005, steadily adding fund commitments through 2009. Funds from 2007 and 2008 could be among the biggest winners.